Dr. Reddy's Q4 Profit Crashes 86%; Cipla Due Today

Dr. Reddy's Posts ₹221 Crore PAT — A Miss by Any Measure [Dr. Reddy's Laboratories](/stock/DRREDDY) reported a Q4 FY26 net profit of ₹221 crore, down 86% year-on-year. Analysts had pencilled in a decline, but not this one — consensus estimates sat around ₹1,035 crore, implying a 34% drop. The actual print was three times worse. That gap between expectation and reality is what moves stocks on results day, and in this case, it moved them down. The company declared a dividend of ₹8 per share, which offers shareholders some consolation but doesn't change the earnings math. Revenue details are still being parsed, but the PAT shock points to a combination of pricing pressure in the US generics market, elevated operating costs, and possibly one-time charges — specifics the management will need to explain clearly on the earnings call. This is not a routine miss. An 86% PAT decline in a quarter, for a company of Dr. Reddy's scale, raises legitimate questions about near-term earnings visibility. Investors who hold the stock for its US pipeline and branded generics story will need to hear a convincing explanation before they recalibrate. Pharma Sector on Edge Before Cipla's Numbers The timing couldn't be sharper. [Cipla](/stock/CIPLA) reports its Q4 FY26 results today, and the market will read those numbers through the lens of Dr. Reddy's miss. Two things are under particular scrutiny: domestic formulations growth — where Cipla has historically outperformed — and the US generics pipeline, which is facing its own pricing headwinds across the industry. NSE: SUNPHARMA, the sector's largest constituent by market cap, is exposed to similar dynamics in the US market. If Cipla's numbers disappoint, the pressure on the Nifty Pharma index could be meaningful. The index had already been navigating uncertainty around US FDA inspections and drug pricing policy shifts. Another earnings miss from a top-tier name would test investor patience with the sector. NSE: DIVISLAB and NSE: AUR...